NCT02365597 2026-06-05An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerJanssen Research & Development, LLCPhase 2 Active not recruiting239 enrolled 32 charts 1 FDA